558 related articles for article (PubMed ID: 9843416)
41. Small molecule antagonists of the urokinase (uPA): urokinase receptor (uPAR) interaction with high reported potencies show only weak effects in cell-based competition assays employing the native uPAR ligand.
De Souza M; Matthews H; Lee JA; Ranson M; Kelso MJ
Bioorg Med Chem; 2011 Apr; 19(8):2549-56. PubMed ID: 21454081
[TBL] [Abstract][Full Text] [Related]
42. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase.
Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654
[TBL] [Abstract][Full Text] [Related]
43. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.
Fazioli F; Resnati M; Sidenius N; Higashimoto Y; Appella E; Blasi F
EMBO J; 1997 Dec; 16(24):7279-86. PubMed ID: 9405357
[TBL] [Abstract][Full Text] [Related]
44. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
[TBL] [Abstract][Full Text] [Related]
45. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
46. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Ploug M; Ellis V; Danø K
Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
[TBL] [Abstract][Full Text] [Related]
47. The receptor for urokinase-plasminogen activator.
Blasi F; Stoppelli MP; Cubellis MV
J Cell Biochem; 1986; 32(3):179-86. PubMed ID: 3023408
[TBL] [Abstract][Full Text] [Related]
48. Tumor cell-conditioned medium stimulates expression of the urokinase receptor in vascular endothelial cells.
Seghezzi G; Marelli R; Mandriota SJ; Nolli ML; Mazzieri R; Mignatti P
J Cell Physiol; 1996 Nov; 169(2):300-8. PubMed ID: 8908197
[TBL] [Abstract][Full Text] [Related]
49. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation.
Ploug M; Østergaard S; Gårdsvoll H; Kovalski K; Holst-Hansen C; Holm A; Ossowski L; Danø K
Biochemistry; 2001 Oct; 40(40):12157-68. PubMed ID: 11580291
[TBL] [Abstract][Full Text] [Related]
50. Kinetics of reciprocal pro-urokinase/plasminogen activation--stimulation by a template formed by the urokinase receptor bound to poly(D-lysine).
Petersen LC
Eur J Biochem; 1997 Apr; 245(2):316-23. PubMed ID: 9151959
[TBL] [Abstract][Full Text] [Related]
51. Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling.
Tarui T; Andronicos N; Czekay RP; Mazar AP; Bdeir K; Parry GC; Kuo A; Loskutoff DJ; Cines DB; Takada Y
J Biol Chem; 2003 Aug; 278(32):29863-72. PubMed ID: 12754207
[TBL] [Abstract][Full Text] [Related]
52. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
Ploug M
Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
[TBL] [Abstract][Full Text] [Related]
53. Unesterified long chain fatty acids inhibit the binding of single chain urokinase to the urokinase receptor.
al-Roof Higazi A; Aceto JF; Kniss D; Upson R; Cohen R; Dichek DA; Cines DB
Biochemistry; 1996 May; 35(21):6884-90. PubMed ID: 8639640
[TBL] [Abstract][Full Text] [Related]
54. The Pseudomonas aeruginosa LasB metalloproteinase regulates the human urokinase-type plasminogen activator receptor through domain-specific endoproteolysis.
Leduc D; Beaufort N; de Bentzmann S; Rousselle JC; Namane A; Chignard M; Pidard D
Infect Immun; 2007 Aug; 75(8):3848-58. PubMed ID: 17517866
[TBL] [Abstract][Full Text] [Related]
55. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
[TBL] [Abstract][Full Text] [Related]
56. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
[TBL] [Abstract][Full Text] [Related]
57. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
[TBL] [Abstract][Full Text] [Related]
58. Functional analysis of the cellular receptor for urokinase in plasminogen activation. Receptor binding has no influence on the zymogenic nature of pro-urokinase.
Ellis V
J Biol Chem; 1996 Jun; 271(25):14779-84. PubMed ID: 8662951
[TBL] [Abstract][Full Text] [Related]
59. Structural investigations of recombinant urokinase growth factor-like domain.
Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
[TBL] [Abstract][Full Text] [Related]
60. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Gårdsvoll H; Ploug M
J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
